Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors

NCT02762981 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT02762981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02762981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors
Lead sponsor
Corcept Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
May 23, 2016
Completion date
September 12, 2020
Enrollment
85 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors